Putin orders to draft over 140,000 men into army this springMilitary & Defense March 30, 10:51
Russia cuts oil output by 200,000 barrels a dayBusiness & Economy March 30, 8:09
Deal of ‘the century’: 150 years since the sale of Russian AlaskaSociety & Culture March 30, 2:55
Russian historical epic Viking to be released in Italy, UKSociety & Culture March 30, 2:11
Putin visits ice cave during Arctic tourSociety & Culture March 30, 0:02
Moscow slams West’s reaction to Russian protests as part of long-planned campaignRussian Politics & Diplomacy March 29, 23:56
Putin orders Defense Ministry and FSB to ensure protection of Russia’s interests in ArcticMilitary & Defense March 29, 21:46
Kiev aware of few chances to win in debt lawsuit case — envoyBusiness & Economy March 29, 20:52
Russian top diplomat dismisses claims about human rights violations in Crimea as liesRussian Politics & Diplomacy March 29, 20:23
KHIMKI, September 6. (ITAR-TASS) – Russian scientists are currently working on the first ever vaccine which could help quit smoking; it may be available in pharmacies in as early as five years. Dmitry Ovchinnikov, Deputy Director General of the company developing the drug, Selecta RUS confirmed: “We’re currently going through the second phase of clinical trials.”
Selecta RUS is a subsidiary of an American innovation company which opened the Khimki branch in 2012. Ovchinnikov said that development of the ‘anti-tobacco’ and other vaccines was moved from the U.S. to Russia, as “experts of required qualification work here.” Favorable financing conditions were also a factor: for instance, the vaccine project has received a grant from Russia’s Ministry of Industry and Trade.
The scientists noted that “existing methods of curing tobacco addiction are ineffective,” adding that the new vaccine will be a breakthrough. The drug makes recipient’s body start producing antibodies which block nicotine before it reaches the brain.
Khimki lab scientists are working on a molecular “nano-container,” which can precisely deliver vaccine components in cells which are responsible for launching immune reaction. Produced anti-bodies bind nicotine contained in blood; the resulting complex becomes too large to bypass the blood–brain barrier, which restrict diffusion of dangerous microscopic objects, such as bacteria and harmful molecules. As a result, nicotine cannot access the brain’s “pleasure center” – thus smoking ceases to bring the feeling of euphoria and satisfaction. The chain of pathological tobacco addiction is thus broken.
Ovchinnikov added that Selecta RUS scientists are also working on other vaccines against other afflictions such as melanoma, type 1 diabetes and hepatitis B.
“Operation of this laboratory is a vivid example of technology transfer to Russia,” said Sergei Filippov, representative of Rusnano. He added that Rusnano owns 12% of SelectaBiosciences, the American company which owns Selecta RUS.